The Phase I/II eNRGy trial: Zenocutuzumab in patients with cancers harboring NRG1 gene fusions
eNRGy is a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusions. Find out more in our latest journal feature here.
eNRGy is a clinical trial of zenocutuzumab for cancer caused by NRG1 gene fusions. Find out more in our latest journal feature here.
SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in pre- and post-menopausal women with ER+, HER2− advanced breast cancer. Parts A and…
Treatment with loncastuximab tesirine yielded high response rates in patients with relapsed or refractory marginal zone lymphoma.
No significant difference in time to treatment was found between White and Black patients with bladder cancer, but there remained a difference in treatment outcomes.
Leland Metheny, MD, discusses how agents such as Iomab-B have potential to shift practice in the hematologic malignancy space.
Treatment with acalabrutinib-based regimens led to long-term benefits in patients with higher-risk CLL, across all lines of therapy.
Asian Americans, Native Hawaiian, and Other Pacific Islanders
Dr Kummar discusses the significance of targeting TP53 Y220C in solid tumors and early data reported with rezatapopt in TP53 Y220C–mutant solid tumors.
An abstract is unavailable.
The University of Texas MD Anderson Cancer Center’s Research Highlights showcases the latest breakthroughs in cancer care, research and prevention. These advances are made possible…
Apalutamide and ADT elicited a 100% biochemical recurrence-free survival rate at 24 months in high-risk localized prostate cancer following radical prostatectomy.